Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115470 | 0.85 | MAPT (0.70) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL124856 | 0.82 | MAPT (0.70) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL5461147 | 0.80 | MAPT (0.67) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL116464 | 0.80 | MAPT (0.64) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL9030307 | 0.80 | MAPT (0.64) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL7455626 | 0.79 | MAPT (0.66) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL7823365 | 0.79 | MAPT (0.77) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL7350226 | 0.78 | MAPT (0.65) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL116971 | 0.77 | MAPK1 (0.65) | MAPTALDH1A1MAPK1PKMKMT2A | |
| SCHEMBL10918468 | 0.77 | ALDH1A1 (0.47) | MAPTALDH1A1MAPK1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524129-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYL ACETONITRILE COMPOUND AND USE THEREOF | Maxunitech Inc. (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250059132-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF | MAXUNITECH INC (CN) | 2025-02-20 | — | — | US | disclosed |
| US-5955461-A | Quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | disclosed |
| US-5750525-A | Quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059132-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF | CYP1B1, CYP1A2, CYP2C9 | MAPT 3935/4885ALDH1A1 209/4885MAPK1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.